Get the Stockscreener App
2.53
1.61%
0.04
After Hours:
2.53
Telomir Pharmaceuticals Inc stock is traded at $2.53, with a volume of 171.18K.
It is up +1.61% in the last 24 hours and down -35.95% over the past month.
Telomir Pharmaceuticals Inc is a pioneering preclinical-stage pharmaceutical company which leads the advancement of age-reversal science. The Company is focused on developing Telomir-1, a novel small molecule designed to lengthen and protect telomeres-the protective DNA end caps of chromosomes that are crucial to cellular aging. As humans and animals age, telomeres naturally shorten, with metal reactivity accelerating this process, increasing the risk of degenerative and age-related diseases. By addressing the underlying causes of aging at the cellular level, Telomir aims to tackle the root of these conditions rather than simply treating their symptoms. Telomir is conducting ongoing preclinical research into Progeria, diabetes, cancer, Alzheimer's disease, osteoarthritis, and others.
See More
Previous Close:
$2.49
Open:
$2.47
24h Volume:
171.18K
Relative Volume:
1.12
Market Cap:
$77.38M
Revenue:
-
Net Income/Loss:
$-13.08M
P/E Ratio:
-5.7292
EPS:
-0.4416
Net Cash Flow:
-
1W Performance:
-2.69%
1M Performance:
-35.95%
6M Performance:
-47.84%
1Y Performance:
-65.20%
1-Day Range:
$2.44
$2.59
1-Week Range:
$2.3536
$2.79
52-Week Range:
$2.3536
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Name
Telomir Pharmaceuticals Inc
Sector
Industry
Phone
786-396-6723
Address
100 SE 2ND ST, MIAMI
Compare TELO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.53 | 77.38M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 126.09B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.91 | 64.01B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.51 | 36.63B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.19 | 30.64B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.77 | 27.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Stock (TELO) Latest News
TELO stock touches 52-week low at $2.35 amid market challenges - Investing.com
TELO stock touches 52-week low at $2.46 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.46 amid market challenges - Investing.com
Corebridge Financial Inc. Has $40,000 Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Comparing Telomir Pharmaceuticals (TELO) and The Competition - Defense World
TELO stock touches 52-week low at $2.59 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $2.59 amid market challenges - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN
SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald
Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener
Telomir-1 shows promise in cancer and chemotherapy study - Investing.com
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India
Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga
Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World
Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa
Telomir-1 shows promise in reversing cell aging - Investing.com India
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune
Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports key preclinical success - Investing.com India
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN
Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times
Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com
Telomir reports stabilization of silver forms for medical use - Investing.com
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat
Telomir Pharmaceuticals Inc Stock (TELO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
2.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):